PMID: 11918502Mar 29, 2002Paper

Discontinuing or switching selective serotonin-reuptake inhibitors

The Annals of Pharmacotherapy
Scott A BullStephen W Hurt

Abstract

To describe reasons for discontinuing or switching selective serotonin-reuptake inhibitors (SSRIs) at 3 and 6 months after starting treatment, and to identify information provided to patients that may help prevent premature discontinuation of medication. Telephone surveys were conducted at 3 and 6 months after patients (n = 672) were started on an SSRI for a new or recurrent case of depression. Significantly more patients discontinued or switched their SSRI because of an adverse effect within the first 3 months of starting (43%) compared with the second 3 months (27%; p = 0.023). The adverse effect most frequently reported as the reason for early discontinuation or switching was drowsiness/fatigue (10.2%), followed by anxiety, headache, and nausea - all at just over 5%. The odds ratio for discontinuation was 61% less in patients who recalled being told to take the medication for at least 6 months compared with those who did not (OR 0.39; p < 0.001). Patients who recalled being informed of potential adverse effects increased their reported incidence of mild to moderate adverse effects by 55% (OR 1.55; p < 0.05) without affecting rates of premature discontinuation (OR 1.06; p = 0.77). Adverse effects are the most frequent reason ...Continue Reading

References

Nov 1, 1993·General Hospital Psychiatry·G E SimonW Barlow
Oct 1, 1996·Archives of General Psychiatry·W KatonE Walker
Feb 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·M HotopfG Lewis
Sep 15, 1998·Psychiatric Services : a Journal of the American Psychiatric Association·K A FairmanF Teitelbaum
Sep 23, 2000·Journal of Clinical Psychopharmacology·M LindenB Schaaf
May 6, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·J S McCombsG L Stimmel

❮ Previous
Next ❯

Citations

Jan 20, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Morgan S BronIlan Fogel
Jul 4, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Vivien M HunotRachel C Churchill
Sep 18, 2007·European Journal of Clinical Pharmacology·E C G van GeffenE R Heerdink
Feb 5, 2009·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Erica C G van GeffenEibert R Heerdink
May 6, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Birgit AblerJulia Stingl
Jul 7, 2011·The Primary Care Companion to CNS Disorders·Shan XingCatherine E Cooke
Nov 2, 2011·Psychological Medicine·S L ClarkE J C G van den Oord
Dec 13, 2005·Clinical Neuropharmacology·Matthew M Parvin, Conrad M Swartz
May 20, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey R BishopAnita H Clayton
Feb 9, 2007·Expert Review of Neurotherapeutics·Chi-Un Pae, Ashwin A Patkar
Feb 10, 2007·Psychosomatic Medicine·Gregory S SayukRay E Clouse
Jul 7, 2014·Attention Deficit and Hyperactivity Disorders·Julia GeisslerTilman Hensch
Jun 24, 2017·Obstetrics and Gynecology·UNKNOWN Committee on Adolescent Health Care
Sep 12, 2019·Frontiers in Behavioral Neuroscience·Olivia Le Moëne, Anders Ågmo
Jan 11, 2007·Cephalalgia : an International Journal of Headache·A Palmieri
Mar 24, 2006·Journal of Child and Adolescent Psychopharmacology·Daniel J Safer, Julie Magno Zito
Dec 8, 2007·Administration and Policy in Mental Health·Carolyn M BrownGlenn A Phillips
Nov 11, 2006·Depression and Anxiety·Laura J Rasmussen-Torvik, Donna D McAlpine
Jan 3, 2012·The Journal of Nervous and Mental Disease·Gloria M ReevesTeodor T Postolache
Mar 20, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Roy H PerlisFrancis J McMahon
Nov 3, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·T SanglierM Toumi
Oct 12, 2013·Journal of the American Society of Nephrology : JASN·Daniel CukorPaul L Kimmel
Mar 13, 2015·Psychopharmacology·Karen HodgsonPeter McGuffin
Dec 21, 2007·The Annals of Pharmacotherapy·Erica C G van GeffenEibert R Heerdink
Jun 17, 2008·Current Medical Research and Opinion·Steven R HahnPeggy W Flowers

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.